Navigation Links
Enobia Pharma Raises $40.1 Million Series B Financing
Date:9/11/2007

MONTREAL and QUEBEC, Sept. 11 /PRNewswire/ -- Enobia Pharma Inc, announced today that it raised $Cdn 40.1 Million in a Series B multi-tranche financing. The proceeds will be used primarily to fund the Company's novel hypophosphatasia drug development program through Phase 2 clinical trials. There is no known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

The financing was co-led by new investors OrbiMed Advisors LLC ("OrbiMed") of New York and CTI Life Sciences Fund of Montreal ("CTI"). The Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000, current investors in the Company, also participated in the round.

Robert Heft, PhD, President and CEO of Enobia said, "With no drug therapy available, hypophosphatasia patients and their families experience prolonged and significant suffering. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for hypophosphatasia."

Jonathan Silverstein, General Partner of OrbiMed said, "We are delighted to be associated with this impressive team working on such a debilitating disease for which there is no cure."

Richard Meadows, Managing Partner of CTI said, "This represents an example of the type of high quality investment opportunity that exists in Quebec and that is capable of attracting the attention and significant investment from our U.S. VC colleagues."

Both Mr. Silverstein and Mr. Meadows will join the newly constituted Board, which also includes: Robert Heft, who previously served on the Board; Fredric Price, also a former Board member, and an investor in this Series B financing who was previously Chairman & CEO of BioMarin Pharmaceutical and Thomas Schuetz, MD, PhD, wh
'/>"/>

SOURCE Enobia Pharma Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
(Date:10/25/2014)... Research and Markets has announced the addition ... Area & by End User - Global Forecast to ... In this report, the global epigenetics market is segmented ... users. The product segments of the epigenetics market included ... and reagents. The subsegments of the enzymes product segment ...
(Date:10/22/2014)... , Oct. 22, 2014 New test ... the in vitro diagnostic (IVD) test industry, especially as ... healthcare market researcher listed more than 25 testing innovations ... be the future of IVD products. Kalorama details the new ... The Worldwide Market for In Vitro Diagnostic Tests ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... works how people can tune in to a single ... solved this week in the journal Nature by ... Psychologists have known for decades about the so-called "cocktail ... in which it was coined. It is the remarkable human ...
... are single-cell plants that comprise nature,s smallest and ... thrive is water, light, and air. When bred ... to wastewater treatment to biofuels. Current microalgae breeding ... allowed by the laws of nature. Scientists at ...
... , Expanded clinical study ...   TMC435 and BMS-986094 (formerly ... in clinical trial , ... on the development of high-value treatments for infectious diseases, ...
Cached Biology Technology:How selective hearing works in the brain 2How selective hearing works in the brain 3Medivir Announces TMC435 in an Expanded Clinical Collaboration 2Medivir Announces TMC435 in an Expanded Clinical Collaboration 3Medivir Announces TMC435 in an Expanded Clinical Collaboration 4
(Date:10/29/2014)... compete with members of their own species. However, ... into their competitive ability. Some individuals are highly ... resources, while others seem to avoid competition, instead ... are left over for them. Moreover, the degree ... to fluctuate considerably over time. A theoretical study ...
(Date:10/28/2014)... in German . ... acquire sufficient food when times are lean? By studying ... d,Ivoire researchers of the Max Planck Institute for Evolutionary ... how great apes can acquire extra energy needed to ... their sleeping nests more en route to breakfast sites ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... the growing demand for organic food products has led to ... of Science, University of Copenhagen, a European research project will ... of a food product and deciding whether or not it ... as olive oil, coffee and wine are sold at a ...
... Among overweight and obese adults, a diet rich ... and other high-fiber foods, significantly reduces markers of inflammation ... by Fred Hutchinson Cancer Research Center. Such a "low-glycemic-load" ... also increases a hormone that helps regulate the metabolism ...
... Every year, a group of anti-whaling nonprofit organizations that ... spend, by conservative estimates, some $25 million on a ... And every year, commercial whaling not only continues, but ... number of whales harvested annually has doubled since the ...
Cached Biology News:Research prevents eco-fraud 2Research prevents eco-fraud 3A diet rich in slowly digested carbs reduces markers of inflammation in overweight and obese adults 2Can we save the whales by putting a price on them? 2Can we save the whales by putting a price on them? 3
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... Rabbit polyclonal to Peroxiredoxin 1 ... family, whose mammalian members have been ... differentiation, and apoptosis. Many isoforms (about ... the amino acid sequence homology, particularly ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Biology Products: